MedTrace Logo

A Study to Evaluate Safety of Exposure to Wegovy During Pregnancy

NCT05872022 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 728

Last updated 2026-01-14

No results posted yet for this study

Summary

This is an observational, prospective Wegovy (semaglutide 2.4 milligram \[mg\]) Pregnancy Registry Study. The aim of this study is to compare the maternal, foetal, and infant outcomes of pregnant women who are exposed to Wegovy during pregnancy for the treatment of obesity or overweight with at least one weight-related comorbid condition with outcomes in an internal comparison cohort of pregnant women with obesity or overweight with at least one weight related comorbid condition at conception and who are not exposed to Wegovy or other glucagon-like peptide-1 receptor agonists (GLP-1 RAs) during pregnancy. Infant outcomes will be assessed throughout the infant's first year of life, with active data collection by the registry occurring at 4 and 12 months after delivery.

Conditions

Interventions

OTHER

No Intervention

This is a non-interventional study, therefore no intervention is used.

Sponsors & Collaborators

Principal Investigators

  • Clinical Transparency (dept. 2834). · Novo Nordisk A/S

Eligibility

Min Age
15 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-05
Primary Completion
2032-10-31
Completion
2032-12-30

Countries

  • United States
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05872022 on ClinicalTrials.gov